AZX 100

Drug Profile

AZX 100

Alternative Names: AZX100

Latest Information Update: 28 Oct 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AzERx
  • Developer Capstone Therapeutics; OrthoLogic
  • Class Amino acids; Muscle relaxants; Peptides
  • Mechanism of Action Heat-shock protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Cerebral vasospasm; Pulmonary fibrosis; Scars; Vascular injuries

Most Recent Events

  • 26 Mar 2014 AZX 100 is available for licensing as of March 2014 (
  • 20 Jan 2012 Discontinued - Phase-II for Scars in USA (Intradermal)
  • 20 Jan 2012 Discontinued - Preclinical for Asthma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top